共 61 条
[1]
Burnet NG(2005)Years of life lost (YLL) from cancer is an important measure of population burden–and should be considered when allocating research funds Br J Cancer 92 241-5
[2]
Jefferies SJ(2005)Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma N Engl J Med 352 987-96
[3]
Benson RJ(2022)Recurrent Glioblastoma treatment: state of the art and future perspectives in the Precision Medicine Era Biomedicines 10 1927-1003
[4]
Stupp R(2005)MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997-64
[5]
Mason WP(2015)MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified Temozolomide Rechallenge in Progressive Glioblastoma: the DIRECTOR trial Clin Cancer Res 21 2057-25
[6]
van den Bent MJ(2018)Review of the neurological benefits of phytocannabinoids Surg Neurol Int 9 91-20
[7]
Leone A(2016)An introduction to the endogenous cannabinoid system Biol Psychiatry 79 516-24
[8]
Colamaria A(2013)Cannabinoid signaling in glioma cells Adv Exp Med Biol 986 209-103
[9]
Fochi NP(2014)Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas J Neurooncol 116 11-203
[10]
Hegi ME(2018)Cannabinoids in Glioblastoma Therapy: New Applications for Old drugs Front Mol Neurosci 11 159-87